Larger-scale studies are needed to validate our findings, to delineate a more precise estimation of the prevalence of RIT1 mutations, to characterize their functional consequences on the RAS pathway and neighboring signaling pathways, and to assess the broader applicability of MEK inhibition in patients with RIT1-mutated vascular malformations. This evidence concerns the gene MAP2K7 and vascular malformation.